Viking Therapeutics, Inc. (VKTX)
37.53
+0.25
(+0.67%)
USD |
NASDAQ |
Dec 10, 16:00
37.46
-0.07
(-0.19%)
After-Hours: 20:00
Viking Therapeutics Cash from Investing (Quarterly): 160.02M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Eli Lilly & Co. | -2.983B |
| Pfizer Inc. | -2.43B |
| Amgen, Inc. | -414.00M |
| Altimmune, Inc. | -149.32M |
| Terns Pharmaceuticals, Inc. | 24.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -94.00M |
| Cash from Financing (Quarterly) | 0.48M |
| Free Cash Flow | -224.58M |
| Free Cash Flow Per Share (Quarterly) | -0.8369 |
| Free Cash Flow to Equity (Quarterly) | -93.88M |
| Free Cash Flow to Firm (Quarterly) | -94.00M |
| Free Cash Flow Yield | -5.34% |